Trial Condition(s):

Colorectal Neoplasms

Regorafenib in subjects with metastatic colorectal cancer (mCRC) who have progressed after standard therapy (REGARD)

Bayer Identifier:

16754

ClinicalTrials.gov Identifier:

NCT01853319

EudraCT Number:

Not Available

Study Completed

Trial Purpose

This is an open-label phase III study of regorafenib in patients with metastatic colorectal cancer (mCRC) who have progressed after all approved standard therapy. The purpose of this study is to provide additional information about the safety profile of Regorafenib.

Inclusion Criteria
- Male or female subjects >/= 18 years of age
 - Life expectancy of at least 3 months
 - Histological or cytological documentation of adenocarcinoma of the colon or rectum
 - Subjects with metastatic colorectal cancer (Stage IV)
 - Progression during or within 3 months following the last administration of approved standard therapies which must include fluoropyrimidine, oxaliplatin, irinotecan, bevacizumab and cetuximab/panitumumab if KRAS WT (WT: wild-type i.e. no KRAS mutation)
 - Eastern Cooperative Oncology Group (ECOG) Performance Status of </= 1
 - Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements
 - Women of childbearing potential and men must agree to use adequate contraception since signing of the inform consent (IC) form until at least 3 months after the last study drug administration
Exclusion Criteria
- Prior treatment with regorafenib
 - Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study drug
 - Pregnant or breast-feeding subjects
 - Congestive heart failure >/= New York Heart Association (NYHA) class 2
 - Myocardial infarction less than 6 months before start of study drug
 - Ongoing infection > Grade 2 Common Terminology Criteria for Adverse Events (CTCAE) v. 4.0
 - Renal failure requiring hemo-or peritoneal dialysis

Trial Summary

Enrollment Goal
100
Trial Dates
black-arrow
Phase
3
Could I receive a placebo?
No
Products
Stivarga (Regorafenib, BAY73-4506)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

ISTANBUL, Turkey, 34899

Status
Completed
 
Locations

Investigative Site

Istanbul, Turkey, 34093

Status
Completed
 
Locations

Investigative Site

Ankara, Turkey, 06500

Status
Completed
 
Locations

Investigative Site

Ankara, Turkey, 06100

Status
Completed
 
Locations

Investigative Site

Bursa, Turkey

Status
Completed
 
Locations

Investigative Site

Kayseri, Turkey

Status
Completed
 
Locations

Investigative Site

Balcali/Adana, Turkey, 01330

Status
Completed
 
Locations

Investigative Site

Gaziantep, Turkey, 27010

Status
Completed
 
Locations

Investigative Site

Izmir, Turkey, 35100

Status
Completed
 
Locations

Investigative Site

Samsun, Turkey

Status
Completed
 
Locations

Investigative Site

Antalya, Turkey

Status
Completed
 

Trial Design